NASDAQ:LEXX Lexaria Bioscience (LEXX) Stock Price, News & Analysis $3.24 -0.05 (-1.52%) Closing price 09/18/2026 04:00 PM EasternExtended Trading$3.10 -0.14 (-4.32%) As of 09/18/2026 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOwnershipSEC Filings About Lexaria Bioscience Stock (NASDAQ:LEXX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Lexaria Bioscience alerts:Sign Up Key Stats Today's Range$3.15▼$3.5250-Day Range$3.10▼$14.1552-Week Range$2.80▼$23.25Volume76,320 shsAverage Volume120,466 shsMarket Capitalization$5.35 millionP/E RatioN/ADividend YieldN/APrice Target$22.50Consensus RatingHold Company Overview Lexaria Bioscience Corp. is a biotechnology company developing drug-delivery technologies designed to improve the absorption and delivery of orally administered active compounds. Its proprietary DehydraTECH platform is intended to enhance bioavailability and may facilitate the delivery of certain compounds across biological barriers, including the blood-brain barrier. The company has researched DehydraTECH applications involving cannabinoids, nicotine, non-steroidal anti-inflammatory drugs, antiviral compounds and other active pharmaceutical ingredients. Lexaria’s work includes laboratory studies, formulation development and human clinical research intended to evaluate the platform’s potential for pharmaceutical, nutraceutical and consumer-health products. Founded in Canada, Lexaria is headquartered in Kelowna, British Columbia, and conducts research and development activities for potential applications in international markets. The company has historically pursued commercialization through product development, licensing and partnerships, while retaining a focus on advancing DehydraTECH as a broadly applicable drug-delivery platform. Lexaria is led by Chief Executive Officer Chris Bunka.AI Generated. May Contain Errors. Read More Lexaria Bioscience Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks29th Percentile Overall ScoreLEXX MarketRank™: Lexaria Bioscience scored higher than 29% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.2 / 5Analyst RatingHold Consensus RatingLexaria Bioscience has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 1 sell rating.Upside PotentialLexaria Bioscience has a consensus price target of $22.50, representing about 594.4% upside from its current price of $3.24.Amount of Analyst CoverageLexaria Bioscience has only been the subject of 1 research reports in the past 90 days.Read more about Lexaria Bioscience's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Lexaria Bioscience are expected to decrease in the coming year, from ($4.05) to ($4.65) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Lexaria Bioscience is -0.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Lexaria Bioscience is -0.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLexaria Bioscience has a P/B Ratio of 1.62. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Lexaria Bioscience's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.35% of the float of Lexaria Bioscience has been sold short.Short Interest Ratio / Days to CoverLexaria Bioscience has a short interest ratio ("days to cover") of 0.32, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Lexaria Bioscience has recently increased by 27.91%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldLexaria Bioscience does not currently pay a dividend.Dividend GrowthLexaria Bioscience does not have a long track record of dividend growth. News and Social Media0.6 / 5News SentimentN/A MarketBeat Follows1 people have added Lexaria Bioscience to their MarketBeat watchlist in the last 30 days. Company Ownership0.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Lexaria Bioscience insiders have not sold or bought any company stock.Percentage Held by Insiders8.39% of the stock of Lexaria Bioscience is held by insiders.Percentage Held by Institutions13.06% of the stock of Lexaria Bioscience is held by institutions.Read more about Lexaria Bioscience's insider trading history. Receive LEXX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lexaria Bioscience and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. LEXX Stock News HeadlinesLexaria Bioscience Corp.: Lexaria Announces Closing of Exercise of Warrants for Approximately $5.9 Million in Gross ProceedsSeptember 9, 2026 | finanznachrichten.deLEXX: Introducing DehydraTECH 3.0September 8, 2026 | finance.yahoo.comLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.September 19 at 1:00 AM | InvestorPlace (Ad)Lexaria Bioscience advances 12% on Australian tax rebateSeptember 1, 2026 | seekingalpha.comLexaria receives $2.6M R&D tax rebate from Australian Tax Office; shares up over 14%September 1, 2026 | msn.comLexaria Bioscience Corp.: Lexaria Enters a Material Transfer Agreement With PegBioAugust 13, 2026 | finanznachrichten.deLexaria Bioscience Stock Rallies Thursday: What Investors Need to KnowAugust 13, 2026 | benzinga.comLexaria Bioscience Corp.: GLP-1 'Arms Race' Intensifies as the Addressable Markets Continue to ExpandJune 19, 2026 | finanznachrichten.deSee More Headlines LEXX Stock Analysis - Frequently Asked Questions How have LEXX shares performed this year? Lexaria Bioscience's stock was trading at $9.2550 at the beginning of 2026. Since then, LEXX stock has decreased by 65.0% and is now trading at $3.24. How were Lexaria Bioscience's earnings last quarter? Lexaria Bioscience Corp. (NASDAQ:LEXX) issued its earnings results on Monday, July, 13th. The company reported ($0.08) earnings per share for the quarter, missing analysts' consensus estimates of ($0.06) by $0.02. When did Lexaria Bioscience's stock split? Lexaria Bioscience's stock reverse split before market open on Monday, August 3rd 2026.A 1-15 reverse split was announced. The number of shares owned by shareholders was adjusted after the market closes on Sunday, August 2nd 2026. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. How do I buy shares of Lexaria Bioscience? Shares of LEXX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Lexaria Bioscience own? Based on aggregate information from My MarketBeat watchlists, some other companies that Lexaria Bioscience investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE), Arista Networks (ANET) and Builders FirstSource (BLDR). Company Calendar Last Earnings7/13/2026Today9/19/2026Next Earnings (Estimated)10/28/2026Fiscal Year End8/31/2027Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (3d) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 As of 3 days ago, LEXX's financial health entered the Red zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:LEXX CIK1348362 Webwww.lexariabioscience.com Phone(250) 765-6424FaxN/AEmployees7Year FoundedN/APrice Target and Rating Average Price Target for Lexaria Bioscience$22.50 High Price Target$22.50 Low Price Target$22.50 Potential Upside/Downside+594.4%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)($5.10) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$11.90 million Net MarginsN/A Pretax Margin-3,987.11% Return on Equity-174.93% Return on Assets-143.89% Debt Debt-to-Equity RatioN/A Current Ratio10.61 Quick Ratio10.61 Sales & Book Value Annual Sales$710 thousand Price / Sales7.53 Cash FlowN/A Price / Cash FlowN/A Book Value$2.00 per share Price / Book1.62Miscellaneous Outstanding Shares1,650,000Free Float1,514,000Market Cap$5.35 million OptionableNot Optionable Beta0.50 Social Links The Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free Report This page (NASDAQ:LEXX) was last updated on 9/19/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lexaria Bioscience Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lexaria Bioscience With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
